It is demonstrated that PARD3-AS1 directly interacts with miR-668-3p to modulate HUVEC proliferation, migration, and invasion, suggesting that PARD3-AS1 may serve as a potential therapeutic target for atherosclerosis.
Abstract
Long non-coding RNAs (lncRNAs) play crucial roles in the onset and progression of cardiovascular disease, particularly atherosclerosis. However, the role of PARD3-AS1 in atherosclerosis remains largely uncharacterized. This study therefore aimed to investigate the impact of the PARD3-AS1/miR-668-3p axis on atherosclerosis. The expression levels of PARD3-AS1 and miR-668-3p in human umbilical vein endothelial cells (HUVECs) were quantified by quantitative real-time polymerase chain reaction (RT-qPCR). HUVEC proliferation was assessed using a Cell Counting Kit-8 (CCK-8) assay and 5-ethynyl-2'-deoxyuridine (EdU) incorporation, and migratory and invasive capacities were evaluated using wound healing and Transwell assays. The interaction between PARD3-AS1 and miR-668-3p was confirmed by bioinformatics analysis and dual-luciferase reporter assays. In addition, serum samples were collected from patients diagnosed with atherosclerosis, and ApoE⁻/⁻ C57BL/6 mice were fed a high-fat diet for 8 weeks to establish a model of atherosclerosis. PARD3-AS1 expression was significantly reduced in the serum of patients with atherosclerosis, whereas miR-668-3p levels were markedly elevated, and the two were negatively correlated. Subsequent experiments confirmed that miR-668-3p effectively reversed the promotion effects of PARD3-AS1 on HUVEC proliferation and migration. In vivo, histological staining showed that the PARD3-AS1 overexpression group exhibited improved endothelial repair. Collectively, these findings demonstrate that PARD3-AS1 directly interacts with miR-668-3p to modulate HUVEC proliferation, migration, and invasion, suggesting that PARD3-AS1 may serve as a potential therapeutic target for atherosclerosis.
It is indicated that SLC12A9-AS1 is abnormally overexpressed in CRC cells and that its knockdown attenuates malignant phenotypes, at least in part through regulation of miR-139-3p.
Shiyu Zhao, Shuai Zhang, Qiong-Feng Tan et al.· Journal of Visualized Experi...· 0 citations
It is suggested that lnc-DNAJC3-AS1 promotes GC progression, at least in part, through the miR-576-5p/LYPLA1 pathway, providing a potential target for GC treatment.
Zhen-Ni Sun, Ya-Sai Yao, Zhi-Jian Xu et al.· American Journal of Cancer R...· 0 citations
To define the functional role of hsa_circ_0054391 (circ54391) in CRC progression and to evaluate its potential as a serum biomarker. Circ54391 was identified from databases and its expression was validated in CRC tissues, cell lines, and serum from healthy controls (
n
= 34), colorectal polyp patients (
n
= 3...
Cheng-Ying Xiong, Zhi-Qiang He, Xiao-Xue Liu et al.· Scientific Reports· 0 citations
In vivo, circPVT1 promoted tumor growth and lung metastasis, which were attenuated by co-expression of miR-195-5p, and molecular analysis of lung metastases confirmed the dysregulation of the circPVT1/miR-195-5p/PDK4 axis within metastatic lesions.
Huanli Hu, Yanan Lu, Yingchuan Sun et al.· Cytotechnology (Dordrecht)· 0 citations
To explore the diagnostic significance of LncRNA GAS6-AS1 in chronic heart failure (CHF) and its molecular mechanism of influencing cardiomyocyte function through the regulation of miR-152-3p. This study incorporated 126 patients diagnosed with CHF and 124 healthy control subjects. The serum level of GAS6-AS1 was deter...
Mi Li, Ning Lu, Lu-Xi Yang et al.· Journal of Cardiothoracic Su...· 0 citations
Functional assays demonstrated that GUSBP11 overexpression enhanced viability, migration, and invasion, whereas its knockdown elicited the opposite phenotype, and the GUSBP11/miR-29c-3p axis exerts a pro-oncogenic influence on GC progression.